Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Adverse effects of anticancer agents that target the VEGF pathway.

Chen HX, Cleck JN.

Nat Rev Clin Oncol. 2009 Aug;6(8):465-77. doi: 10.1038/nrclinonc.2009.94. Epub 2009 Jul 7. Review.

PMID:
19581909
2.

The role of antiangiogenesis therapy: bevacizumab and beyond.

Cort├ęs-Funes H.

Clin Transl Oncol. 2009 Jun;11(6):349-55. Review.

PMID:
19531449
3.

Drug insight: VEGF as a therapeutic target for breast cancer.

Schneider BP, Sledge GW Jr.

Nat Clin Pract Oncol. 2007 Mar;4(3):181-9. Review.

PMID:
17327858
4.

Mechanisms of adverse effects of anti-VEGF therapy for cancer.

Kamba T, McDonald DM.

Br J Cancer. 2007 Jun 18;96(12):1788-95. Epub 2007 May 22. Review.

5.

[Role of VEGFR-TKIs in the treatment of renal cell carcinoma].

Kondo T.

Nihon Jinzo Gakkai Shi. 2012;54(5):574-80. Review. Japanese. No abstract available.

PMID:
22991835
6.

Targeted therapy in advanced non-small-cell lung cancer.

Gettinger S.

Semin Respir Crit Care Med. 2008 Jun;29(3):291-301. doi: 10.1055/s-2008-1076749. Review.

PMID:
18506667
7.
8.

Cardiovascular toxicity of new agents.

Maitland ML.

Clin Adv Hematol Oncol. 2008 Sep;6(9):657-9. No abstract available.

PMID:
18827788
9.

Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies.

Girardi F, Franceschi E, Brandes AA.

Oncologist. 2010;15(7):683-94. doi: 10.1634/theoncologist.2009-0235. Epub 2010 Jun 14. Review.

10.

Signaling inhibitors in metastatic renal cell carcinoma.

Escudier B.

Cancer J. 2008 Sep-Oct;14(5):325-9. doi: 10.1097/PPO.0b013e3181867605.

PMID:
18836338
11.

Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?

Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM.

Oncologist. 2010;15(2):130-41. doi: 10.1634/theoncologist.2009-0252. Epub 2010 Feb 5. Review.

12.

Tolerability of first-line therapy for metastatic renal cell carcinoma.

Porta C, Szczylik C.

Cancer Treat Rev. 2009 May;35(3):297-307. doi: 10.1016/j.ctrv.2008.12.003. Epub 2009 Feb 26. Review.

PMID:
19249157
13.

Targeting angiogenesis in esophagogastric adenocarcinoma.

Okines AF, Reynolds AR, Cunningham D.

Oncologist. 2011;16(6):844-58. doi: 10.1634/theoncologist.2010-0387. Epub 2011 May 31. Review.

14.

VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.

English BC, Price DK, Figg WD.

Cancer Biol Ther. 2009 Jul;8(13):1214-25. Epub 2009 Jul 4. No abstract available.

15.

Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.

Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, Ellis LM.

Lancet Oncol. 2010 Apr;11(4):373-82. doi: 10.1016/S1470-2045(09)70341-9. Epub 2010 Feb 18. Review.

PMID:
20171141
16.

Progress in the management of advanced renal cell carcinoma (RCC).

Tong TQ, Rohde D, Peter S.

Aktuelle Urol. 2010 Jan;41 Suppl 1:S57-60. doi: 10.1055/s-0030-1247237. Epub 2010 Jan 21. Review.

PMID:
20094957
17.

Two new drugs for renal cell carcinoma.

[No authors listed]

Med Lett Drugs Ther. 2007 Feb 26;49(1255):18-20. No abstract available.

PMID:
17325624
18.

Renal toxicity of targeted therapies.

Kelly RJ, Billemont B, Rixe O.

Target Oncol. 2009 Apr;4(2):121-33. doi: 10.1007/s11523-009-0109-x. Epub 2009 May 6. Review.

PMID:
19421832
19.

[Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].

Reig M, Matilla A, Bustamante J, Castells L, de La Mata M, Delgado M, Moreno JM, Forner A, Varela M.

Gastroenterol Hepatol. 2010 Dec;33(10):741-52. doi: 10.1016/j.gastrohep.2010.05.007. Epub 2010 Sep 18. Spanish. No abstract available.

PMID:
20851505
20.

Angiogenesis regulated by VEGF and its receptors and its clinical application.

Shibuya M.

Rinsho Ketsueki. 2009 May;50(5):404-12. Review. No abstract available.

PMID:
19483401

Supplemental Content

Support Center